Botulinum toxin therapy in congenital blepharospasm

Area of Science:

• Ophthalmology
• Pediatric Neurology

Background:

• Essential blepharospasm is typically treated with botulinum toxin in adults.
• Congenital blepharospasm and its treatment in infants have not been previously documented in medical literature.

Observation:

• A 4-week-old infant presented with complete inability to open her eyes and involuntary eyelid closure.
• Standard neuropediatric evaluations yielded no significant findings.
• A periorbital injection of botulinum toxin was administered at 2 months of age to mitigate the risk of amblyopia.

Findings:

• Following the botulinum toxin injection, the infant exhibited noticeable bilateral eye opening and the ability to make eye contact within four days.
• At a 3-year follow-up, the patient maintained open eyelids without any adverse effects from the botulinum toxin therapy.

Implications:

• This case suggests that botulinum toxin injections may be a safe and effective treatment for congenital blepharospasm in infants.
• Early intervention with botulinum toxin could prevent visual impairment in infants diagnosed with this condition.
• Further research is warranted to establish the long-term efficacy and safety profile of botulinum toxin for infantile blepharospasm.